Latest technology reporting
Evidence-led coverage of biotechnology, AI infrastructure, energy, robotics, devices and brain–computer interfaces.
-
Elranatamab Clears a Phase III Hurdle—With the Hardest Questions Still Open
Pfizer says its BCMA-targeting bispecific antibody delayed progression versus three active regimens in relapsed multiple myeloma, but the result is still topline and overall-survival data are immature.
-
Partial Reprogramming Looks Different in Every Organ—and That Is the Point
A new analysis of old-mouse tissue data finds encouraging liver and kidney signals alongside a spleen warning, underscoring why “younger” gene activity is not the same thing as a safe rejuvenation therapy.
-
Retired Nuclear Sites Become Candidates for Germany’s AI Factories
PreussenElektra and NVIDIA will assess retired German nuclear sites for AI data centres. The proposal reuses infrastructure, not nuclear power.
-
AMD and Intel Merge Their CPU AI Software Paths Around oneDNN
AMD will bring ZenDNN work into oneDNN, the shared PyTorch path for x86 CPU AI. The collaboration targets portability, not a guaranteed speedup.
-
Southeast Asia’s Clean-Tech Boom Is Pivoting From Solar to Batteries
IEA projects Southeast Asia’s clean-tech market could exceed $80 billion by 2035 as EV and battery manufacturing overtakes solar investment.
-
Thousands of AI Agents Turn a Mouse-Brain Atlas Into Testable Leads
Thousands of GPT-Rosalind agents analysed a mouse-brain CRISPR atlas in 32 minutes, producing testable leads that still need laboratory validation.
-
CRISPR’s Rare Mistakes Change From Cell to Cell and Organ to Organ
Single-cell and mouse-organ profiling found CRISPR off-target edits can vary by cell and tissue, exposing blind spots in bulk safety tests.
-
FDA Moves Talazoparib–Enzalutamide Earlier in HRR-Mutated Prostate Cancer
FDA approved talazoparib plus enzalutamide earlier in HRR-mutated metastatic prostate cancer after TALAPRO-3 delayed progression.
-
OSK Reprogramming Repairs Mouse Cartilage Without Erasing Cell Identity
OSK partial reprogramming protected cartilage in cultured cells and mouse osteoarthritis models. It remains preclinical gene-delivery research.
-
AstraZeneca and Oracle Bring AI Trial Matching Into Clinical Workflows
AstraZeneca and Oracle plan to connect real-world health data, clinical workflows and AI for trial recruitment, safety monitoring and earlier diagnosis. The first hypertension programme is a deployment test, not proof of improved outcomes.
-
Amazon Backs a 960 MW Indiana Nuclear Proposal That Still Has to Clear Reality
Amazon will fund milestones as AEP and X-energy study a proposed 12-reactor Xe-100 plant in Indiana. The 960 MW figure is a development target, not licensed or operating capacity.
-
SpaceX’s $40 Billion Chip Lease Turns AI Hardware Into Infrastructure Debt
An Apollo-managed affiliate will buy AI chips and servers and lease them to SpaceX under a roughly $40 billion principal-payment agreement. It is equipment finance, not $40 billion of immediate revenue or delivered computing capacity.